- Is multidisciplinary treatment effective for hepatocellular carcinoma with portal vein tumor thrombus?
-
Choe WH
- KMID: 2528290
- J Liver Cancer.
- 2022 Mar;22(1):1-3.
- doi: 10.17998/jlc.2022.03.15
-
- CITED
-
- Close
- SHARE
-
- Close
- Recent updates on the classification of hepatoblastoma according to the International Pediatric Liver Tumors Consensus
-
Jeong SU, Kang HJ
- KMID: 2528293
- J Liver Cancer.
- 2022 Mar;22(1):23-29.
- doi: 10.17998/jlc.2022.02.24
Hepatoblastoma is the most common pediatric liver malignancy and usually occurs within the first 3 years of life. In recent years, the overall incidence of hepatoblastoma has exhibited the greatest... -
- CITED
-
- Close
- SHARE
-
- Close
- A clinical and pathological update on hepatocellular carcinoma
-
Renne SL, Tommaso LD
- KMID: 2528292
- J Liver Cancer.
- 2022 Mar;22(1):14-22.
- doi: 10.17998/jlc.2022.03.18
It is estimated that more than 1 million individuals will be affected annually by hepatocellular carcinoma (HCC) by 2025. HCC can be broadly grouped into two major molecular subgroups, each... -
- CITED
-
- Close
- SHARE
-
- Close
- Radioembolization for hepatocellular carcinoma: what clinicians need to know
-
Choi JW, Kim HC
- KMID: 2528291
- J Liver Cancer.
- 2022 Mar;22(1):4-13.
- doi: 10.17998/jlc.2022.01.16
Transarterial radioembolization (TARE) with yttrium 90 (90Y) has been used in the management of hepatocellular carcinoma (HCC) for more than 10 years in Korea. There are two types of 90Y... -
- CITED
-
- Close
- SHARE
-
- Close
- Sorafenib combined with radiation therapy for advanced hepatocellular carcinoma with portal and hepatic vein invasion extending to the inferior vena cava: a complete response case according to modified RECIST criteria
-
Cho Y, Kim BH, Kim TH, Koh YH, Park JW
- KMID: 2528298
- J Liver Cancer.
- 2022 Mar;22(1):63-68.
- doi: 10.17998/jlc.2022.01.18
The prognosis of patients with advanced hepatocellular carcinoma (HCC) with tumor thrombus extending to the inferior vena cava (IVC) is extremely poor. Herein, we present a rare case of advanced... -
- CITED
-
- Close
- SHARE
-
- Close
- Concurrent transarterial radioembolization and combination atezolizumab/ bevacizumab treatment of infiltrative hepatocellular carcinoma with portal vein tumor thrombosis: a case report
-
Park MK, Yu SJ
- KMID: 2528299
- J Liver Cancer.
- 2022 Mar;22(1):69-74.
- doi: 10.17998/jlc.2022.03.09
Treatment options for advanced hepatocellular carcinoma (HCC) have been rapidly evolving. Herein, we describe a patient with advanced HCC and portal vein tumor thrombosis (PVTT) who responded decisively to a... -
- CITED
-
- Close
- SHARE
-
- Close
- Complete response to local therapy for advanced hepatocellular carcinoma with lung metastasis: a case report
-
Kim D, Park S, Sohn W, Hong HP, Kim BI
- KMID: 2528296
- J Liver Cancer.
- 2022 Mar;22(1):51-56.
- doi: 10.17998/jlc.2021.12.28
The concept of oligometastasis is widely accepted for various types of solid tumors; accordingly, better outcomes can be anticipated with aggressive local interventions. The treatment of advanced hepatocellular carcinoma (HCC)... -
- CITED
-
- Close
- SHARE
-
- Close
- Long-term survival after CCRT and HAIC followed by ALPPS for hepatocellular carcinoma with portal vein invasion: a case report
-
Kim IJ, Yoo SH, Lee JI, Lee KS, Lee HW, Lim JH
- KMID: 2528301
- J Liver Cancer.
- 2022 Mar;22(1):84-90.
- doi: 10.17998/jlc.2022.03.07
There are various methods for treating advanced hepatocellular carcinoma with portal vein invasion, such as systemic chemotherapy, transarterial chemoembolization, transarterial radioembolization, and concurrent chemoradiotherapy. These methods have similar clinical efficacy... -
- CITED
-
- Close
- SHARE
-
- Close
- The effects of immune checkpoint modulators on the clinical course of patients with resectable hepatocellular carcinoma
-
An J, Kang HJ, Yu E, Lee HC, Shim JH
- KMID: 2528295
- J Liver Cancer.
- 2022 Mar;22(1):40-50.
- doi: 10.17998/jlc.2022.03.06
Background/Aim: Immune checkpoint proteins regulating T-cell mediated anti-tumor immunity have been reported to affect clinical outcomes in multiple malignancies. This study aimed to investigate the prognostic effect of histological expression... -
- CITED
-
- Close
- SHARE
-
- Close
- Multidisciplinary treatment with immune checkpoint inhibitors for advanced stage hepatocellular carcinoma
-
Lee A, Lee J, Yang H, Sung SY, Jeon CH, Kim SH, Choi MH, Lee YJ, Chun HJ, Bae SH
- KMID: 2528300
- J Liver Cancer.
- 2022 Mar;22(1):75-83.
- doi: 10.17998/jlc.2022.03.04
Hepatocellular carcinoma (HCC) is a cytotoxic chemotherapy-resistant tumor and most HCCs arise in a background of liver cirrhosis of various causes. Although the IMBrave150 trial showed remarkable advancements in the... -
- CITED
-
- Close
- SHARE
-
- Close
- A case report of advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy and sorafenib combination therapy followed by metastasectomy of lung and muscle metastases
-
Moon SY, Han SY, Baek YH
- KMID: 2528297
- J Liver Cancer.
- 2022 Mar;22(1):57-62.
- doi: 10.17998/jlc.2021.12.20
Currently, various tyrosine kinase inhibitors and immune checkpoint inhibitors have been suggested in the treatment guidelines for advanced hepatocellular carcinoma (HCC). However, sorafenib was the only systemic drug approved 10... -
- CITED
-
- Close
- SHARE
-
- Close
- Diagnostic performance of serum exosomal miRNA-720 in hepatocellular carcinoma
-
Jang JW, Kim JM, Kim HS, Kim JS, Han JW, Lee SK, Nam H, Sung PS, Bae SH, Choi JY, Yoon SK
- KMID: 2528294
- J Liver Cancer.
- 2022 Mar;22(1):30-39.
- doi: 10.17998/jlc.2022.02.25
Background/Aim: Hepatocellular carcinoma (HCC) is associated with poor prognosis, largely due to late detection. Highly accurate biomarkers are urgently needed to detect early-stage HCC. Our study aims to explore the... -
- CITED
-
- Close
- SHARE
-
- Close
